Next Article in Journal
Do Global Regulators Hold the Key to Production of Bacterial Secondary Metabolites?
Next Article in Special Issue
New Urea Derivatives as Potential Antimicrobial Agents: Synthesis, Biological Evaluation, and Molecular Docking Studies
Previous Article in Journal
Actinomycete-Derived Polyketides as a Source of Antibiotics and Lead Structures for the Development of New Antimicrobial Drugs
Previous Article in Special Issue
Using Colistin as a Trojan Horse: Inactivation of Gram-Negative Bacteria with Chlorophyllin
Open AccessArticle

The Effect of 2-Thiocyanatopyridine Derivative 11026103 on Burkholderia Cenocepacia: Resistance Mechanisms and Systemic Impact

1
Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, 15400 Prague, Czech Republic
2
Department of Microbiology, Faculty of Science, University of Manitoba, 213 Buller Building, Winnipeg, MB R3T 2N2, Canada
3
Department of Biology and Biotechnology, University of Pavia, Via Ferrata 9, 27100 Pavia, Italy
4
Bach Institute of Biochemistry, Research Center of Biotechnology of the Russian Academy of Sciences, Leninsky Prospect 33, Moscow 119071, Russia
5
Department of Medical Microbiology and Infectious Diseases, Rady Faculty of Health Sciences, University of Manitoba, 727 McDermot Avenue, Winnipeg, MB R3E 3P5, Canada
*
Author to whom correspondence should be addressed.
Antibiotics 2019, 8(4), 159; https://doi.org/10.3390/antibiotics8040159
Received: 9 August 2019 / Revised: 9 September 2019 / Accepted: 17 September 2019 / Published: 21 September 2019
Bacteria of the Burkholderia cepacia complex (Bcc) are associated with significant decline of lung functions in cystic fibrosis patients. Bcc infections are virtually impossible to eradicate due to their irresponsiveness to antibiotics. The 2-thiocyanatopyridine derivative 11026103 is a novel, synthetic compound active against Burkholderia cenocepacia. To characterize mechanisms of resistance to 11026103, B. cenocepacia was subjected to chemical mutagenesis, followed by whole genome sequencing. Parallel mutations in resistant isolates were localized in a regulatory protein of the efflux system Resistance-Nodulation-Division (RND)-9 (BCAM1948), RNA polymerase sigma factor (BCAL2462) and its cognate putative anti-sigma factor (BCAL2461). Transcriptomic analysis identified positive regulation of a major facilitator superfamily (MFS) efflux system BCAL1510-1512 by BCAL2462. Artificial overexpression of both efflux systems increased resistance to the compound. The effect of 11026103 on B. cenocepacia was analyzed by RNA-Seq and a competitive fitness assay utilizing an essential gene knockdown mutant library. 11026103 exerted a pleiotropic effect on transcription including profound downregulation of cluster of orthologous groups (COG) category “Translation, ribosomal structure, and biogenesis”. The competitive fitness assay identified many genes which modulated susceptibility to 11026103. In summary, 11026103 exerts a pleiotropic cellular response in B. cenocepacia which can be prevented by efflux system-mediated export. View Full-Text
Keywords: Burkholderia cenocepacia; chemical mutagenesis; RNA-Seq; whole-genome sequencing; Tn-Seq; chemical genetics Burkholderia cenocepacia; chemical mutagenesis; RNA-Seq; whole-genome sequencing; Tn-Seq; chemical genetics
Show Figures

Figure 1

MDPI and ACS Style

Nunvar, J.; Hogan, A.M.; Buroni, S.; Savina, S.; Makarov, V.; Cardona, S.T.; Drevinek, P. The Effect of 2-Thiocyanatopyridine Derivative 11026103 on Burkholderia Cenocepacia: Resistance Mechanisms and Systemic Impact. Antibiotics 2019, 8, 159.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop